Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aspire Biopharma Holdings, Inc. - Common Stock (NQ:ASBP)

0.4950 -0.0730 (-12.85%)
Streaming Delayed Price Updated: 3:58 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aspire Biopharma Holdings, Inc. - Common Stock

Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice (“GMP”) Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform
Via ACCESS Newswire
An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation
New York, New York--(Newsfile Corp. - March 11, 2025) - Aspire Biopharma Holdings, Inc. (NASDAQ: ASBP) ("Aspire" or the "Company")... 
Via Newsfile
Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin
Via ACCESS Newswire
Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement
Via ACCESS Newswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.